PACE-CME

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

RAAS inhibition in patients with kidney disease Balancing the benefits and risks
RestartResume
10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME
  • Overview

    Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.

  • Educational information

    This lecture by prof. Patrick Rossignol was part of a CME accredited symposium "RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes" held during ERA-EDTA 2019 in Budapest, Hungary.

  • Faculty

    Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free